Diaz, Nuria http://orcid.org/0009-0005-0331-3402
Perez, Carlos http://orcid.org/0009-0002-3362-7654
Escribano, Ana Maria
Sanz, Gema
Priego, Julian
Lafuente, Celia
Barberis, Mario
Calle, Luis
Espinosa, Juan Felix http://orcid.org/0000-0002-1436-7298
Priest, Birgit T.
Zhang, Hong Y.
Nosie, Amanda K.
Haas, Joseph V.
Cannady, Ellen
Borel, Anthony
Schultze, Albert E. http://orcid.org/0000-0001-6437-9396
Sauder, J. Michael http://orcid.org/0000-0002-0254-4955
Hendle, Jörg
Weichert, Ken
Nicholls, Stephen J.
Michael, Laura F. http://orcid.org/0000-0002-4152-4199
Article History
Received: 14 July 2023
Accepted: 4 April 2024
First Online: 8 May 2024
Competing interests
: N.D., C.P., A.M.E., G.S., J.P., C.L., M.B., L.C., J.F.E., B.T.P., H.Y.Z., A.K.N., J.V.H., E.C., A.B., A.E.S., J.M.S., K.W., J.H. and L.F.M. are employees and minor shareholders in Eli Lilly. S.J.N. has received research support from Amgen, Anthera, AstraZeneca, Cerenis Therapeutics, CSL Behring, Eli Lilly, Esperion Therapeutics, Infraredx, New Amsterdam Pharma, Novartis, Resverlogix and Sanofi Regeneron, and is a consultant for Akcea Therapeutics, Amgen, AstraZeneca, Boehringer Ingelheim, CSL Behring, Eli Lilly, Esperion Therapeutics, Kowa, Merck, Novo Nordisk, Pfizer, Sanofi Regeneron and Takeda.